DeepMed Research

UNIVERSITY OF MIAMI

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1925-01-01

Employees: 10K

Market Cap: -

Website: https://continue.miami.edu/packagedetail.aspx

Clinical Trials

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Carfilzomib
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Montelukast
Drug: Daratumumab
Biological: Autologous Stem Cell Transplant (ASCT)

First Posted Date: 2020-02-13

Last Posted Date: 2025-05-06

Lead Sponsor: University of Miami

Target Recruit Count: 310

Registration Number: NCT04268498

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

and more 4 locations

Baby Item Learning and Development Study

Not Applicable

Active, not recruiting

Conditions: Infant Development

Interventions: Other: Baby Carrier
Other: Baby Bouncer
Other: Infant t-shirts with Language Environment Analysis (LENA) audio recorders

First Posted Date: 2020-02-12

Last Posted Date: 2025-05-21

Lead Sponsor: University of Miami

Target Recruit Count: 100

Registration Number: NCT04267302

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Marker Driven Selection of Patients for Prostate Biopsy and Management

Recruiting

Conditions: PSA
Elevated PSA
Prostate Cancer

First Posted Date: 2020-01-27

Last Posted Date: 2025-04-03

Lead Sponsor: University of Miami

Target Recruit Count: 300

Registration Number: NCT04240327

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

High-Speed Yoga and Executive Function

Not Applicable

Completed

Conditions: Executive Dysfunction
Quality of Life
Parkinson Disease

Interventions: Behavioral: High-speed yoga multi-directional yoga

First Posted Date: 2020-01-02

Last Posted Date: 2022-05-25

Lead Sponsor: University of Miami

Target Recruit Count: 30

Registration Number: NCT04215900

Locations: 🇺🇸
Max Orovitz Laboratories, Coral Gables, Florida, United States

Diet Intervention for Crohn's Disease Patient

Not Applicable

Completed

Conditions: Crohn Disease

Interventions: Other: CD LFD
Behavioral: Diet Counseling
Behavioral: Dyadic Psychological Support (DPS)

First Posted Date: 2019-12-30

Last Posted Date: 2024-02-29

Lead Sponsor: University of Miami

Target Recruit Count: 300

Registration Number: NCT04213729

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Orthostatic, Respiratory, Balance-Intervention

Not Applicable

Completed

Conditions: Spinal Cord Injuries

Interventions: Other: Inspiratory Muscle Training (IMT)

First Posted Date: 2019-12-24

Last Posted Date: 2020-08-11

Lead Sponsor: University of Miami

Target Recruit Count: 18

Registration Number: NCT04210063

Locations: 🇺🇸
The Miami Project to Cure Paralysis, Miami, Florida, United States

Mindfulness Training for Small Teams

Not Applicable

Completed

Conditions: Cognitive Change

Interventions: Behavioral: MBAT-I
Behavioral: MBAT-T

First Posted Date: 2019-12-24

Last Posted Date: 2022-09-01

Lead Sponsor: University of Miami

Target Recruit Count: 356

Registration Number: NCT04210076

Locations: 🇺🇸
University of Miami, Coral Gables, Florida, United States

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

Completed

Conditions: Epicardial Fat

First Posted Date: 2019-12-16

Last Posted Date: 2023-05-10

Lead Sponsor: University of Miami

Target Recruit Count: 80

Registration Number: NCT04200625

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Wound Dressings for Hidradenitis Suppurativa

Not Applicable

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Device: Cutimed Sorbact Hydroactive B wound dressing
Device: Cutimed Siltect wound dressing
Device: Sorbion Sana multi-star wound dressing

First Posted Date: 2019-12-11

Last Posted Date: 2023-03-14

Lead Sponsor: University of Miami

Target Recruit Count: 28

Registration Number: NCT04194541

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Phase 2

Terminated

Conditions: Diffuse Large B Cell Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia
Marginal Zone Lymphoma

Interventions: Drug: Acalabrutinib
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2019-12-06

Last Posted Date: 2022-09-19

Lead Sponsor: University of Miami

Target Recruit Count: 2

Registration Number: NCT04189952

Locations: 🇺🇸
University of Miami, Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy